Evidence map›Paper›PMID 35953849›Full record

ArticleMicrobial cell factories2022

From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris.

Nora Tir, Lina Heistinger, Clemens Grünwald-Gruber, Leo A Jakob, Stephan Dickgiesser, Nicolas Rasche, Diethard Mattanovich

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Microorganisms · 2024
    Review
  7. A Cost-EffectiveBioengineering (Basel, Switzerland) · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Nora TirChristian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Lina HeistingerChristian Doppler Laboratory for Innovative Immunotherapeutics, Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Clemens Grünwald-GruberUniversity of Natural Resources and Life Sciences, Vienna Core Facility Mass Spectrometry, Muthgasse 18, 1190, Vienna, Austria.
Leo A JakobDepartment of Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria.
Stephan DickgiesserADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany.
Nicolas RascheADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany.
Diethard MattanovichDepartment of Biotechnology, Institute of Microbiology and Microbial Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190, Vienna, Austria. diethard.mattanovich@boku.ac.at.
BOKU University · ATETH Zurich · CHMerck (Germany) · DETarget (Germany) · DE

Funding

Austrian Science Fund W1224Austrian Science Fund FWF W 1224Christian Doppler Forschungsgesellschaft CD-I2T
6 · The paper itself

Abstract

backgroundExpansion of the genetic code is a frequently employed approach for the modification of recombinant protein properties. It involves reassignment of a codon to another, e.g., unnatural, amino acid and requires the action of a pair of orthogonal tRNA and aminoacyl tRNA synthetase modified to recognize only the desired amino acid. This approach was applied for the production of trastuzumab IgG carrying p-azido-L-phenylalanine (pAzF) in the industrial yeast Pichia pastoris. Combining the knowledge of protein folding and secretion with bioreactor cultivations, the aim of the work was to make the production of monoclonal antibodies with an expanded genetic code cost-effective on a laboratory scale.

resultsCo-translational transport of proteins into the endoplasmic reticulum through secretion signal prepeptide change and overexpression of lumenal chaperones Kar2p and Lhs1p improved the production of trastuzumab IgG and its Fab fragment with incorporated pAzF. In the case of Fab, a knockout of vacuolar targeting for protein degradation further increased protein yield. Fed-batch bioreactor cultivations of engineered P. pastoris strains increased IgG and IgG

conclusionsPichia pastoris was successfully employed for cost-effective laboratory-scale production of a monoclonal antibody with an unnatural amino acid. Applying the results of this work in glycoengineered strains, and taking further steps in process development opens great possibilities for utilizing P. pastoris in the development of antibodies for subsequent conjugations with, e.g., bioactive payloads.

Indexed as

Amino AcidsPichiaAntibodies, MonoclonalAntibody FormationImmunoglobulin GRecombinant ProteinsSaccharomyces cerevisiaeSaccharomycetalesTrastuzumabAmino AcidsAntibodies, MonoclonalImmunoglobulin GRecombinant ProteinsTrastuzumabBioreactor cultivationMonoclonal antibodyPichia pastorisStrain engineeringUnnatural amino acid

Identifiers

PMID35953849
PMCPMC9367057
OpenAlexW4291021067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.